Conversely, DLL4/NICD activation by olmesartan, an angiotensin II receptor blocker, attenuated transverse aortic constriction-induced cardiac remodeling in mice (13) and monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy in rats (14). This evidence concerns the gene DLL4 and pulmonary arterial hypertension.